الفهرس 
Diabetes MellitusOnly 14 pages are availabe for public view
 |  | from | 16 |  |  |
| | | from | 16 | | |
Abstract
Chronic kidney disease (CKD) is increasingly categorized as a
worldwide public health dispute with adverse outcomes on patients’
health and huge financial burden. Once nephropathy develops,
approximately 20–40% of patients step forward to ESRD. Therefore,
novel biomarkers are needed to enable early risk recognition in diabetic
nephropathy, so that those at advanced risk of progression to ESRD are
identified at early stages of nephropathy development.
Thus, the aim of the present work was to study the levels of fibroblast
growth factor 23 (FGF23) in type 2 diabetic patients with different stages
of diabetic kidney disease and to evaluate its diagnostic value as a
biomarker for early detection of diabetic kidney disease in comparison
with albuminuria.
The current study was carried out on 85 individuals who attended to
outpatient clinics of Internal medicine department at El-Menoufia
university hospital during the period from April 2018 to April 2019. The
selected subjects were divided into three groups: group I included 10
healthy normal non diabetic control subjects, group II included 25
patients who had type 2 diabetes mellitus with normoalbuminuria, group
III included subjects who had diabetic kidney disease and subdivided into
2 sections: 25 Subjects with type 2 DM with microalbuminuria & 25
Subjects with type 2 DM with macroalbuminuria.
As regard the results of serum FGF23, there was progressively
increase in the mean level of FGF23 in diabetic groups. Where, the mean
levels of FGF23 in normoalbuminuric, microalbuminuric and macroalbuminuric group were 171.4±30.09, 337.8±55.72 and 794.4±185
(pg /ml) respectively compared to controls of 98.5±12.92 (pg /ml). The
ANOVA test showed statistically significant difference in the mean level of FGF23 among different diabetic groups and in diabetic groups more than controls.